share_log

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60

Benzinga ·  Aug 12 17:41  · Ratings

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $62 to $60.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment